{"id":"flutiform-250-10-micrograms","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness/anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate binds to glucocorticoid receptors in the airways, suppressing inflammatory mediator release and reducing airway edema and mucus production. Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle, causing relaxation and bronchodilation. Together, they provide both anti-inflammatory and bronchodilator effects for maintenance asthma control.","oneSentence":"Flutiform combines fluticasone propionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:08.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy in patients requiring combination inhaled corticosteroid and long-acting beta-2 agonist"}]},"trialDetails":[{"nctId":"NCT00734318","phase":"PHASE3","title":"Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2008-09","conditions":"Asthma, Bronchial","enrollment":1667},{"nctId":"NCT01946620","phase":"PHASE3","title":"A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2013-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1767},{"nctId":"NCT02388373","phase":"PHASE4","title":"A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2014-07","conditions":"Asthma","enrollment":225},{"nctId":"NCT00747318","phase":"PHASE3","title":"A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-09","conditions":"Asthma","enrollment":280},{"nctId":"NCT00657774","phase":"PHASE1","title":"A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands","status":"COMPLETED","sponsor":"SkyePharma AG","startDate":"2008-04","conditions":"Asthma","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Flutiform 250/10 micrograms","genericName":"Flutiform 250/10 micrograms","companyName":"Mundipharma Research Limited","companyId":"mundipharma-research-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Flutiform combines fluticasone propionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma. Used for Asthma maintenance therapy in patients requiring combination inhaled corticosteroid and long-acting beta-2 agonist.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}